Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
In this study, we present a case of renal failure in a patient who was on a tenofovir-containing regimen, resulting in extremely high tenofovir exposure and prolonged tenofovir monotherapy. We considered this case report important because exposure to tenofovir monotherapy might have consequences for future discontinuation strategies in cases of renal failure.
Ter Heine
Rob
R
Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, the Netherlands. Rob@terHeine.nl
Huitema
Alwin Dr
AD
Jansen
Robert S
RS
Smits
Paul Hm
PH
van Gorp
Eric Cm
EC
Wagenaar
Jiri Fp
JF
Beijnen
Jos H
JH
Mulder
Jan W
JW
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D024882:Drug Resistance, Viral / Q000187:drug effects; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects / Q000493:pharmacokinetics*; D051437:Renal Insufficiency / Q000139:chemically induced*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics; D000068698:Tenofovir; D013997:Time Factors; D028761:Withholding Treatment
D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine